


Amendments to the Claims

This listing will replace all prior versions, and listings, of the claims in the application:

Listing of Claims:

Claim 1 (Currently amended): The triptolide Triptolide derivatives having the structure represented by the formula (1) shown as below, or pharmaceutically acceptable salts thereof, or their optical diastereoisomers:




Wherein wherein C-5 and C-6 are connected through single or double carbon-carbon bond; when C-5 and C-6 are connected by single bond, X and Y independently represent hydrogen, oxygen, hydroxyl, halogen, alkoxy, mercapto, -NR₁R₂, -SR, -OCOR, -OSO₂OR, or -OPO(OH)₂ linked to C-5 or C-6, in which R is -(CH₂)_nCO₂Na, -(CH₂)_nCO₂K 或 or -(CH₂)_nCH₃, and n=1-6;

Z is hydrogen, oxygen, hydroxyl, halogen, alkoxy, mercapto, -N R₁R₂, -SR, -OCOR, -OSO₂OR, or -OPO(OH)₂ linked to C-14, in which R is -(CH₂)_nCO₂Na, -(CH₂)_nCO₂K *** - (CH₂)_nCH₃, n=1-6;


In the above formula (1), “-“ that attaches to “X”, “Y” and “Z” represents the stereochemistry orientations “—” and “……..” as well; and

X and Y are not allowed to be hydrogen at the same time.


Claim 2 (Currently amended): ~~The triptolide~~ Triptolide derivatives according to of claim 1, wherein the configuration of X is a (R), that of Y is (R) or (S), and Z is β -OH(R) shown as formula (2):




Claim 3 (Currently amended): ~~The triptolide~~ Triptolide derivatives according to of claim 1, wherein the configuration of X is α (R), that of Y (R) or (S), and Z is α -OH(s) shown as formula (3):



Claim 4 (Currently amended): ~~The triptolide~~ Triptolide derivatives according to of claim 1, wherein the configuration of X is a (R), that of Y (R) or (S), and Z is O shown as formula (4):



Claim 5 (Currently amended): ~~The triptolide~~ Triptolide derivatives according to of claim 1, wherein C-5 and C-6 are connected by double bond, and the configuration of Z is R or S, or Z=O as shown formula (5):



Claim 6 (Currently amended): ~~The triptolide~~ Triptolide derivatives according to of claim 1, which comprise including the following: (5R)-5-hydroxytriptonide, (5R)-5-hydroxytriptolide, (5R)-5-hydroxy-14-epitriptolide, $\Delta^{5,6}$ -dehydrotriptonide, $\Delta^{5,6}$ -dehydrotriptolide, $\Delta^{5,6}$ -dehydro-14-epitriptolide, (5R,6S)-5,6-epoxytriptonide, (5R,6S)-5,6-epoxytriptolide, (5R,6S)-5,6-epoxy-14-epitriptolide, *cis*-(5R,6S)-5,6dihydroxytriptonide, *cis*-(5R,6S)-5,6-dihydroxytriptolide, *cis*-(5R,6S)-5,6-dihydroxy-14epitriptolide.

Claim 7 (Currently amended): A The application of the triptolide derivatives of claim 1 in preparing antiflamable agent, immunosuppressant agent or other pharmaceutical composition prepared from the triptolide derivatives of claim 1, compositions in treating related diseases.

Claim 8 (Currently amended): A method of treating at least one of The application of claim 7, wherein the related diseases include autoimmune diseases, including arthritis, diseases (arthritis, systemic lupus erythematosus, chronic nephritis, diabetes); diabetes and inflammatory diseases, including AIDS, diseases (AIDS, virus hepatitis); allergy; hepatitis, and allergies and skin diseases, and cardiovascular diseases, diseases and transplant rejection, as well as rejections, and

anti-fertility and immune related diseases. diseases which comprises administrating the pharmaceutical composition of Claim 7.

Claim 9 (New): A pharmaceutical composition according to claim 7 which comprises at least one of and antiflamable agent, and an immunosuppressant.

Claim 10 (New): A method of treating at least one of an autoimmune disease and an inflammatory disease which comprises administrating the pharmaceutical composition of Claim 9.